These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22071785)

  • 1. Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.
    Okamoto I; Yoshioka H; Takeda K; Satouchi M; Yamamoto N; Seto T; Kasahara K; Miyazaki M; Kitamura R; Ohyama A; Hokoda N; Nakayama H; Yoshihara E; Nakagawa K
    J Thorac Oncol; 2012 Feb; 7(2):427-33. PubMed ID: 22071785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
    Blumenschein GR; Reckamp K; Stephenson GJ; O'Rourke T; Gladish G; McGreivy J; Sun YN; Ye Y; Parson M; Sandler A
    Clin Cancer Res; 2010 Jan; 16(1):279-90. PubMed ID: 20028752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
    Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer.
    Crawford J; Swanson P; Schwarzenberger P; Sandler A; Prager D; Zhang K; Freeman DJ; Johnson CW; Krishnan K; Johnson D
    J Thorac Oncol; 2013 Dec; 8(12):1510-8. PubMed ID: 24389433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
    Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J
    J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
    Doebele RC; Conkling P; Traynor AM; Otterson GA; Zhao Y; Wind S; Stopfer P; Kaiser R; Camidge DR
    Ann Oncol; 2012 Aug; 23(8):2094-2102. PubMed ID: 22345119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
    Hida T; Tamiya M; Nishio M; Yamamoto N; Hirashima T; Horai T; Tanii H; Shi MM; Kobayashi K; Horio Y
    Cancer Sci; 2011 Apr; 102(4):845-51. PubMed ID: 21205086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
    Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
    J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
    Zhao Y; Foster NR; Meyers JP; Thomas SP; Northfelt DW; Rowland KM; Mattar BI; Johnson DB; Molina JR; Mandrekar SJ; Schild SE; Bearden JD; Aubry MC; Adjei AA
    J Thorac Oncol; 2015 Jan; 10(1):172-80. PubMed ID: 25247339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
    Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
    Goffin JR; Nicholas G; Mates M; Tu D; Chen E; Laurie SA; Juergens R; Robinson A; Goss G; Reaume M; Sun S; Christink K; Maize C; MacFarlan S; Sun X; Ritter H; Seymour L; Bradbury PA
    Invest New Drugs; 2019 Jun; 37(3):498-506. PubMed ID: 30317534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
    Laurie SA; Gauthier I; Arnold A; Shepherd FA; Ellis PM; Chen E; Goss G; Powers J; Walsh W; Tu D; Robertson J; Puchalski TA; Seymour L
    J Clin Oncol; 2008 Apr; 26(11):1871-8. PubMed ID: 18398152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
    Novello S; Scagliotti GV; Sydorenko O; Vynnychenko I; Volovat C; Schneider CP; Blackhall F; McCoy S; Hei YJ; Spigel DR
    J Thorac Oncol; 2014 Aug; 9(8):1154-61. PubMed ID: 25157768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).
    Langer CJ; McAleer CA; Bonjo CA; Litwin S; Millenson M; Kosierowski R; Blankstein K; Alexander R; Ozols RF
    Eur J Cancer; 2000 Jan; 36(2):183-93. PubMed ID: 10741276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.